NCT03748212Unknown1 期
A Randomized, Open-label, Fed, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-385 in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 52
- 试验地点
- 1
- 主要终点
- AUCt of Carvedilol
研究概览
简要总结
A randomized, open-label, fed, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-385 in healthy volunteers
详细描述
To healthy subjects of 52, following treatments are administered dosing in each period and wash-out period is a minimum of 7 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •A healthy adult aged over 19 at the time of screening
- •Weight over 55, with BMI between 17.5kg/m² and 30.5kg/m²
- •Subject who has no congenital or chronic disease within the last 3 years and no medical symptoms or signs as a result of medical examination
- •Suitable subject who is determined at the time of screening by examiners according to the characteristics of the medicine such as hematology test, blood chemistry test, urine test, virus / bacteriological test, vital signs, electrocardiogram test
- •Subject who signed the written consent form approved by Chonbuk National University Hospital IRB to participate in this study with full understanding of the purpose and contents of the examination prior to participation of the clinical trial
- •Subject who has the ability and willingness to participate in the clinical trial
排除标准
- •Subject who has (or has histories of) clinically significant blood, kidney, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, liver, mental, neurological or allergic diseases(except for asymptomatic seasonal allergy at the time of administration) or evidence(except for simple dental history such as dental calculus, impacted tooth, wisdom tooth, etc.)
- •Subject with a history of gastrointestinal disorders(esophageal achalasia or esophagus stenosis, Crohn's disease) or gastrointestinal surgery(except for simple appendicitis surgery or hernia surgery or tooth extraction surgery) that may affect the absorption of drug
- •Subject who shows the following values as a result of laboratory tests
- •*ALT or AST > 2 times upper limit of normal range
- •Subject who has a history of regular alcohol consumption in excess of 210 g/week within 6 months of screening
- •Subject who smokes more than one pack of cigarette a day within 6 months of screening
- •Subject who took other clinical trial drugs or bioequivalence test drugs within 3 months before the first administration of clinical trial drug
- •Subject who conform to the specific items below
- •systolic blood pressure less than 90 mmHg, greater than 140 mmHg or diastolic blood pressure less than 60 mmHg or greater than 90 mmHg in a sitting position
- •Severe bradycardia (less than 50 beats/minute)
- •Subject who has significant alcohol abuse or drug abuse within a year of screening
- •Subject who took drugs which are known as disturbing drug metabolism within 30 days prior to the first administration of clinical trial drug.
- •Subject who uses any of other drugs, including over-the-counter medications and prescription medications within 10 days prior to first administration of clinical trial drug.
- •Subject who donated whole blood within 2 months prior to first administration of clinical trial drug or blood components within 1 month prior to first administration of clinical trial drug
- •Subject who is hypersensitive to the components of a clinical trial drug or clinical trial drug itself.
- •Subject who does not consent to reliable contraception during the entire period of clinical trial and until 7th day of administration of clinical trial drug.
- •Subject who is not able to consume high-fat meal provided during the clinical trial
- •Any other subject who is decided by investigators to be ineligible in clinical trial
研究组 & 干预措施
Group 1
Active Comparator
D935 Cap. 1T
干预措施: D935 Cap. 1T (Drug)
Group 2
Experimental
CKD-385 Tab. 1T
干预措施: CKD-385 Tab. 1T (Drug)
结局指标
主要结局
AUCt of Carvedilol
时间窗: Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs
Area under the plasma concentration of Carvedilol verses time curve from time zero to time of last quantifiable concentration
Cmax of Carvedilol
时间窗: Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs
Maximum plasma concentration of Carvedilol
次要结局
- AUCinf of Carvedilol(Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs)
- t1/2 of Carvedilol(Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs)
- Vd/F of Carvedilol(Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs)
- Tmax of Carvedilol(Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs)
- CL/F of Carvedilol(Pre-dose(0hr), 1, 2, 3, 4, 5, 6, 7, 8, 10, 12, 24, 48hrs)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Clinical Study to Compare the Pharmacokinetic Characteristics and Safety Between CKD-357 and D578 in Healthy VolunteersAcute Coronary SyndromeNCT03671941Chong Kun Dang Pharmaceutical31
已完成
1 期
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fed ConditionsEndocrine, Nutritional and Metabolic DiseasesNCT06399068Chong Kun Dang Pharmaceutical31
已完成
1 期
Clinical Study to Evaluate Pharmacokinetic Profiles and Safety of CKD-387 Under Fasting ConditionEndocrine, Nutritional and Metabolic DiseasesNCT05673369Chong Kun Dang Pharmaceutical40
已完成
1 期
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-387 in Healthy Volunteers Under Fasting ConditionsEndocrine, Nutritional and Metabolic DiseasesNCT06399055Chong Kun Dang Pharmaceutical37
已完成
1 期
A Study to Evaluate the Pharmacokinetics and Safety of HCP1704 in Healthy SubjectsHealth, SubjectiveNCT04081857Hanmi Pharmaceutical Company Limited48